投资者关系活动记录表 证券代码：300485 证券简称：赛升药业 北京赛升药业股份有限公司 投资者关系活动记录表 编号：2023-002 | | 特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访  业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 活动参与人员 | 线上参与本公司 2022 年度网上业绩说明会的投资者 | | 时间 | 2023 年 04 月 13 日（星期四） | | 地点 | 公司通过全景网"全景•路演天下"（http://rs.p5w.net）采用 | | | 网络远程的方式召开业绩说明会 | | 上市公司 | 董事长兼总经理马骉先生，副总经理兼财务总监马丽女士，副总 | | 接待人员姓名 | 经理兼董事会秘书王雪峰先生，独立董事董岳阳先生，保荐代表 | | | 人赵轶女士 公司于 2023 年 04 月 13 日（星期四）15:00-17:00 采用网 | | | 络远程方式召开 2022 年度业绩网上说明会，就 2022 年度经营情 | | | 况与 ...

Financial Performance - The company's revenue for 2022 was approximately ¥734.55 million, a decrease of 30.10% compared to ¥1,050.81 million in 2021[31]. - Net profit attributable to shareholders was approximately ¥204.73 million, down 49.11% from ¥402.27 million in the previous year[31]. - The net cash flow from operating activities was approximately ¥110.43 million, a decline of 39.75% compared to ¥183.30 million in 2021[31]. - Basic earnings per share decreased to ¥0.43, down 48.81% from ¥0.84 in 2021[31]. - The company reported a significant drop in net profit excluding non-recurring gains and losses, which was approximately ¥330.39 thousand, down 99.68% from ¥104.34 million in 2021[31]. - The weighted average return on net assets was 6.18%, down from 13.47% in the previous year, reflecting a decrease of 7.29%[31]. - The company experienced a quarterly revenue decline in Q4 2022, with revenue of approximately ¥135.31 million, compared to ¥215.89 million in Q3 2022[33]. - The company achieved operating revenue of 734.55 million yuan, a decrease of 30.1% compared to the same period last year[62]. - The net profit attributable to shareholders was 204.74 million yuan, down 49.11% year-on-year[62]. - The gross profit margin for the pharmaceutical manufacturing sector was 77.03%, down 6.07% from the previous year[88]. - Sales volume in the pharmaceutical manufacturing sector dropped by 29.47% to 3,014.76 million units in 2022[90]. Dividend Distribution - The company reported a profit distribution plan, proposing a cash dividend of 0.86 CNY per 10 shares (including tax) based on a total of 481,666,400 shares[10]. - The total cash dividend for the year was 41,423,310.40 RMB, representing 100% of the total profit distribution[197]. - The cash dividend policy requires a minimum of 20% of profit distribution to be allocated as cash dividends during profit distribution[199]. - The board approved a profit distribution plan, distributing a cash dividend of 0.86 CNY per 10 shares, totaling 41,423,310.40 CNY[200]. - The company has no plans for stock dividends or capital increases in the current profit distribution[196]. Market and Industry Challenges - The pharmaceutical industry faces significant policy risks due to increasing government regulations and reforms, impacting market access and operational requirements[4]. - There is a risk of product price decline due to changes in drug procurement systems and medical insurance payment conditions, which could adversely affect profitability[6]. - The company’s marketing network covers major cities in China, but faces challenges in market expansion due to changing drug demand and increased competition[5]. - The pharmaceutical industry in China saw a revenue of approximately 29.11 trillion in 2022, a year-on-year decrease of 1.6%[42]. - The total profit for the pharmaceutical industry was approximately 4.29 billion, down 31.8% compared to the previous year, indicating significant pressure on profitability[42]. Research and Development - New drug development is a priority, but it involves lengthy processes and risks of failure, necessitating careful project selection and resource allocation[9]. - The company is committed to enhancing R&D capabilities and has plans to accelerate the development of new products and technologies[9]. - The company is actively involved in the development of new products, including a recombinant shingles vaccine that has entered clinical research in the U.S.[48]. - The company has established a proprietary biopharmaceutical purification technology platform, enhancing its core process technology advantages[59]. - The company is conducting preclinical research on a new cardiovascular drug aimed at improving microcirculation and is optimizing production processes[82]. - The company is advancing preclinical studies for a new thrombolytic drug, focusing on key process parameters and product stability[82]. - The company has established a platform for peptide drug design and synthesis, successfully completing the synthesis of target anti-tumor drugs[84]. - The company aims to apply for more than 2 invention patents this year while steadily advancing the progress of its R&D projects[135]. Strategic Initiatives - The company is exploring strategic partnerships or acquisitions to achieve its long-term goals in response to potential risks[10]. - The company is actively exploring potential mergers and acquisitions to enhance its market position and product offerings[31]. - The company aims to leverage its resources and expertise through strategic partnerships to enhance sustainable development and competitive advantage[45]. - The company is committed to expanding its market presence and enhancing its comprehensive competitive capabilities through strategic collaborations[74]. - The company is actively pursuing market expansion and investment opportunities through strategic acquisitions[180]. Human Resources and Talent Management - The company is focused on retaining core personnel to safeguard its technological capabilities amid increasing competition for talent[10]. - The company has implemented a talent cultivation plan with initial positive results, focusing on customized training for different talent types[139]. - The company has established a systematic internship base with universities to strengthen the training of technical employees and provide practical teaching opportunities[141]. - The company is optimizing its personnel structure by increasing the recruitment of employees with bachelor's degrees or higher and establishing a succession mechanism[140]. Operational Efficiency - The company has established a comprehensive procurement, production, and sales system to ensure operational efficiency[50]. - The company maintains an independent operational structure, with a complete production, sales, and R&D system, ensuring autonomous business capabilities[155]. - The company has established a complete and independent financial management system, with dedicated accounting personnel and independent tax obligations[156]. Governance and Compliance - The company has a clear governance structure with independent boards and committees, adhering to legal and regulatory requirements[156]. - The company’s board of directors includes experienced professionals, with the chairman and general manager holding significant shares, totaling 238,464,000 shares[161]. - The company has not reported any changes in the tenure of directors or senior management during the reporting period[162]. - The audit committee reviewed the 2021 fourth quarter audit report and fundraising account status[184]. Future Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 10% to 1.32 billion RMB, driven by new product launches and market expansion[167]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[167]. - The launch of two new products is scheduled for Q2 2023, anticipated to contribute an additional 200 million RMB in revenue[167].

出席本次年度网上说明会的人员有：公司董事长兼总经理马骉先生，副总经 理兼财务总监马丽女士，副总经理兼董事会秘书王雪峰先生，独立董事董岳阳先 生，保荐代表人赵轶女士。 为充分尊重投资者，提高交流的针对性，现就公司2022年度业绩网上说明会 提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023 年04月07日（星期五）12:00前访问https://ir.p5w.net/zj/，进入问题征集专 题页面进行提问。公司将在本次年度业绩说明会上对投资者普遍关注的问题进行 回答。 证券代码：300485 证券简称：赛升药业 公告编号：2023-018 北京赛升药业股份有限公司 关于举行 2022 年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京赛升药业股份有限公司(以下简称"公司")《2022年年度报告》及年度 报告摘要已于2023年03月30日刊登于中国证监会指定的创业板信息披露网站巨 潮资讯网（http://www.cninfo.com.cn）。 为使广大投资者进一步了解公司2022年经营情况，公司定于2023年04月 ...

投资者关系活动记录表 证券代码：300485 证券简称：赛升药业 北京赛升药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------|---------------------------------|---------------------------------| | \n投资者关系活动 | 编号： 2015001 \n■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 中邮基金 容杰 | | | 人员姓名 | 西南证券 何治力 | | | | 华商基金 张晓、陈恒 | | | | 中融人寿 汪虹、董凤亮 | | | | 银河证券 张金洋 | | | | 信达证券 李惜浣 | | | | 国寿安保基金 吴坚、王雪莹 | | | | 华夏基金 王泽实、张钧 | | | | 新华基金 潮礼君 | | 投资者关系活动记录表 | --- | --- | --- ...

投资者关系活动记录表 证券代码：300485 证券简称：赛升药业 北京赛升药业股份有限公司 投资者关系活动记录表 编号：2016001 | --- | --- | --- | |----------------|----------------------|------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 华创证券：张文录、宋凯、王逸萌、刘宇腾、故宏亮 | | | 嘉实基金：颜媛 | | | | 东兴基金：邓巧 | | | | 泓德基金：操昭煦 | | | | 长盛基金：张伟光 | | | | 浦银安盛：刘诗瑶 | | | 参与单位名称及 | 江铜集团：邢连云 | | | 人员姓名 | 中融人寿：汪虹 | | | | 中国人寿资产：赵文龙 | | | | 天风证券：王卓、贾帅 | | | | 华融 ...

Financial Performance - Revenue for Q3 2022 was CNY 215,891,125.90, a decrease of 24.92% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 18,443,537.92, down 64.79% year-on-year[3] - Basic earnings per share decreased by 63.64% to CNY 0.04[3] - The net profit for the third quarter of 2022 reached CNY 250,180,916.41, an increase of 88.17% compared to CNY 132,956,669.56 in the same period last year[10] - The total profit amounted to CNY 283,045,644.26, reflecting a growth of 79.19% from CNY 157,957,424.57 year-on-year[10] - The operating profit increased by 79.19% to CNY 283,067,954.35, driven by higher investment income from joint ventures and changes in the fair value of financial assets[10] - The company's basic earnings per share rose to CNY 0.52, marking a 79.31% increase from CNY 0.29 in the previous year[11] - Total operating revenue for the current period was ¥599,234,034.97, a decrease of 26.0% compared to ¥809,479,013.21 in the previous period[23] - Net profit for the current period was ¥250,180,916.41, an increase of 88.5% compared to ¥132,956,669.56 in the previous period[24] - The company reported a basic and diluted earnings per share of ¥0.52, up from ¥0.29 in the previous period[25] Assets and Equity - Total assets increased by 4.97% to CNY 3,570,725,389.62 compared to the end of the previous year[4] - Owner's equity attributable to shareholders rose by 5.40% to CNY 3,420,096,193.97[4] - Total assets rose to ¥3,570,725,389.62, compared to ¥3,401,649,422.52 in the previous period, reflecting a growth of 5.0%[21] - The company's total equity increased to ¥3,456,594,955.95 from ¥3,283,105,830.65 in the previous period[21] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 90,144,873.36, down 28.47%[3] - Cash and cash equivalents at the end of the period decreased by 69.72% to CNY 119,581,121.81, attributed to a reduction in cash reserves[12] - The company's cash and cash equivalents decreased from CNY 161,543,438.37 at the beginning of the year to CNY 119,581,121.81 by September 30, 2022, a decline of approximately 26%[19] - The net cash flow from operating activities for the current period is ¥90,144,873.36, a decrease of 28.5% compared to ¥126,025,973.11 in the previous period[26] - Cash and cash equivalents at the end of the period amount to ¥119,581,121.81, down from ¥394,967,167.05 in the previous period[27] Investment and Expenses - Investment income increased by 208.29% to CNY 90,531,418.02, mainly due to higher equity method investment income[9] - Sales expenses decreased by 31.18% to CNY 294,296,573.46, attributed to reduced marketing activities[9] - Research and development expenses were ¥79,555,905.38, slightly down from ¥80,473,801.38 in the previous period[23] - The company achieved an investment income of ¥90,531,418.02, significantly up from ¥29,365,431.82 in the previous period[24] Inventory and Liabilities - Inventory decreased by 30.61% to CNY 85,392,157.97, primarily due to reduced raw material purchases[9] - The total current assets decreased from CNY 1,530,193,553.81 to CNY 1,464,545,372.82, a reduction of about 4.3%[19] - Total liabilities decreased to ¥114,130,433.67 from ¥118,543,591.87 in the previous period[21] Strategic Developments - The company established a venture capital fund with an investment of CNY 10 million, and acquired an 18% stake in Beijing Haijing Biomedical Technology Co., Ltd. for CNY 7.2 million[15] - The company signed a strategic cooperation framework agreement with Beijing Tianguangshi Biotechnology Co., Ltd. to enhance collaboration in drug development and production[16] - The subsidiary Junyuan Pharmaceutical obtained a drug production license from the Liaoning Provincial Drug Administration[16] - The company is currently conducting Phase I clinical trials for a humanized anti-VEGF monoclonal antibody injection, which is a key product under development[17] Other Financial Metrics - Non-recurring gains and losses totaled CNY 7,781,671.26 for the current period[6] - The income tax expense rose by 31.45% to CNY 32,864,727.85, driven by the increase in profits[10] - The total comprehensive income for the period was CNY 253,797,441.83, an increase of 91.17% compared to CNY 132,759,296.71 in the previous year[11] - The cash paid for purchasing goods and services decreased by 32.32% to CNY 84,357,054.43, reflecting a reduction in raw material procurement[11] - The company experienced a foreign exchange impact on cash and cash equivalents of ¥2,457,965.42, compared to -¥134,172.85 in the previous period[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 34,687[13] - The largest shareholder, Ma Jiao, holds 49.51% of the shares, totaling 238,464,000 shares[13] Audit Status - The company has not undergone an audit for the third quarter report[28]

北京赛升药业股份有限公司 2022 年半年度报告全文 北京赛升药业股份有限公司 2022 年半年度报告 2022-070 2022 年 8 月 1 北京赛升药业股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人马骉、主管会计工作负责人马丽及会计机构负责人(会计主管 人员)栗建华声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告如有涉及未来计划等前瞻性陈述，均不构成公司对投资者的实质承 诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异。公司已在本报告"第三节管理层讨论与分析"之 "十、公司面临的风险和应对措施"部分，对可能面临的风险进行详细描述， 敬请投资者注意风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | --- | | 第一节 重要提示、目录和释义 | 2 | | --- | --- | | ...

北京赛升药业股份有限公司 2022 年第一季度报告全文 证券代码：300485 证券简称：赛升药业 公告编号：2022-042 北京赛升药业股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保 证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 (二)非经常性损益项目和金额 √ 适用 □ 不适用 单位：元 | 项目 | 本报告期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部 | 2,718,143.33 | | | 分） | | | | 计入当期损益的政府补助（与公司正常经营业务密切相关， 符合国家政策规定、按照一定标准定额或定量持续享受的政 | 5,954,099.23 | | | 府补助 ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥521,930,586.60, representing a 7.72% increase compared to ¥484,520,630.90 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥85,333,463.28, a slight increase of 0.53% from ¥84,884,458.26 in the previous year[21]. - The net profit after deducting non-recurring gains and losses decreased by 32.89% to ¥51,614,391.46 from ¥76,915,530.41 in the same period last year[21]. - The net cash flow from operating activities was ¥82,364,563.18, down 42.08% from ¥142,201,118.48 in the previous year[21]. - The basic earnings per share remained unchanged at ¥0.18, consistent with the previous year[21]. - The diluted earnings per share also remained unchanged at ¥0.18, consistent with the previous year[21]. - The weighted average return on net assets was 3.01%, a decrease of 0.12% from 3.13% in the previous year[21]. - The total operating revenue for the first half of 2021 was CNY 521,930,586.60, an increase of 7.7% compared to CNY 484,520,630.90 in the first half of 2020[167]. - The company reported a net profit of 11,649,462.1 yuan for the first half of 2021, with total assets amounting to 22,608,698.7 yuan[89]. - The total comprehensive income for the first half of 2021 was CNY 81,788,656.96, compared to CNY 82,889,889.88 in the same period last year[169]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,026,206,534.72, an increase of 1.17% from ¥2,991,062,511.44 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company increased by 1.92% to ¥2,858,136,029.58 from ¥2,804,427,300.38 at the end of the previous year[21]. - The company's long-term equity investments increased to ¥468,016,729.95, accounting for 15.47% of total assets, up from 14.77% the previous year[57]. - Total liabilities decreased to CNY 125,784,628.92 from CNY 141,128,369.42, a reduction of about 10.9%[159]. - Owner's equity increased to CNY 2,900,421,905.80, up from CNY 2,849,934,142.02, representing a growth of approximately 1.8%[160]. - The cash and cash equivalents decreased significantly to CNY 376,546,597.51 from CNY 597,014,473.07, a decline of about 37.0%[162]. Research and Development - Research and development expenses surged by 125.08% to ¥56,488,696.35, reflecting the company's increased investment in ongoing research projects[50]. - The company is actively involved in the development of new products, including a recombinant shingles vaccine and a peptide drug for acute ischemic stroke[33]. - The company has established partnerships with several international medical system manufacturers for trade cooperation[32]. - The company has strengthened its R&D capabilities through partnerships with universities and research institutions, accelerating product development[43]. - The company has established a proprietary technology platform for the purification of biological macromolecules, which includes advanced techniques such as affinity chromatography and monoclonal antibody purification[46]. Market Position and Strategy - The company achieved over 50% market share in cardiovascular products and immunomodulators, establishing itself as a market leader[38]. - The sales model focuses on "on-site investment + academic promotion," with a distribution network targeting hospitals through distributors[36]. - The company is expected to maintain a significant market share in its immunomodulator products, particularly Thymosin Injection[38]. - The pharmaceutical industry in China has been experiencing continuous growth driven by increased medical demand and consumption upgrades[36]. - The company is exploring new investment opportunities to further strengthen its market position and financial performance[68]. Investment and Financial Management - The total amount of raised funds is CNY 1,080,944,700 after deducting issuance costs of CNY 72,855,300[75]. - Cumulative investment of raised funds reached CNY 708,010,000, with CNY 570,900,000 invested during the reporting period[74]. - The company invested CNY 463 million in bank wealth management products using raised funds, with a total of CNY 1.13 billion in wealth management products, and no overdue amounts reported[82]. - The company has made significant equity investments during the reporting period, including a long-term investment in Green Bamboo Bio-pharmaceutical Co., amounting to ¥20,000,000, representing a 9.82% stake[65]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period[84][85]. Compliance and Governance - The company is committed to adhering to the disclosure requirements set by the Shenzhen Stock Exchange for pharmaceutical and biological products[38]. - The company has established robust internal control systems and external audits to ensure the safety of its overseas assets[58]. - The company has ensured timely, accurate, and complete disclosure of the use of raised funds, with no violations reported[79]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[103]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[116]. Future Outlook - The company plans to focus on new product development and market expansion strategies in the upcoming quarters[184]. - The management expressed optimism about future growth prospects despite the current financial challenges[184]. - The company is exploring strategic acquisitions to enhance its competitive position in the market[192]. - The company plans to expand its market presence and invest in new product development to drive future growth[192].